BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Financial Performance - BioNTech is expected to report fourth-quarter earnings of $0.25 per share, a significant decrease from$1.90 per share in the same period last year [1] - The company projects quarterly revenue of $1.15 billion, down from$1.48 billion a year earlier [1] Regulatory Developments - The U.S. FDA has placed a clinical hold on BioNTech's Investigational New Drug application for the RNA-based vaccine BNT165e, which is intended for malaria prevention [2] - Following the FDA's announcement, BioNTech shares fell by 3.4%, closing at $110.83 [2] Analyst Ratings - Wells Fargo analyst Mohit Bansal initiated coverage with an Overweight rating and a price target of$172 [4] - Canaccord Genuity analyst William Maughan maintained a Buy rating and slightly increased the price target from $171 to$171.44 [4] - JP Morgan analyst Jessica Fye maintained a Neutral rating and reduced the price target from $124 to$122 [4] - Evercore ISI Group analyst Cory Kasimov upgraded the stock from In-Line to Outperform, raising the price target from $110 to$125 [4] - Morgan Stanley analyst Terence Flynn upgraded the stock from Equal-Weight to Overweight, increasing the price target from $93 to$145 [4]